← Back to Search

Virus Therapy

Phage Therapy for Urinary Tract Infection

Phase 1 & 2

Waitlist Available

Led By Gregory German, MD PhD FRCPC

Research Sponsored by Gregory German

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of recurrent chronic urinary tract infections with severe long term effects

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 90 days

Awards & highlights

Study Summary

This trial will test whether a 3-phage cocktail can treat and prevent a drug-resistant urinary tract infection with serious long-term effects.

Who is the study for?

This trial is for English-speaking individuals with chronic, recurrent urinary tract infections that have serious long-term effects. Participants must be willing to follow the study protocol but cannot join if they have advanced kidney disease, abnormal liver tests, use a urinary stent or catheter regularly, are pregnant, part of another trial, or allergic to phage products.Check my eligibility

What is being tested?

The trial is testing a new treatment called phage therapy using a cocktail of bacteriophages (viruses that target bacteria) named HP3, HP3.1 and ES19. It's given orally, topically into the urethra opening and directly into the bladder to treat drug-resistant UTI.See study design

What are the potential side effects?

Potential side effects may include reactions at the application sites such as irritation or discomfort. Since this is an early-phase trial assessing safety and effectiveness of phage therapy for UTIs, detailed side effect profiles will be studied.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have chronic urinary tract infections with severe long-term effects.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 90 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~90 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety and Tolerability

Secondary outcome measures

Clinical and microbial response

Trial Design

1Treatment groups

Experimental Treatment

Group I: Open Label ArmExperimental Treatment1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Applied Health Research CentreOTHER

22 Previous Clinical Trials

71,035 Total Patients Enrolled

Gregory GermanLead Sponsor

Unity Health TorontoLead Sponsor

537 Previous Clinical Trials

447,538 Total Patients Enrolled

Media Library

Phage Therapy (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05537519 — Phase 1 & 2

Urinary Tract Infection Research Study Groups: Open Label Arm

Urinary Tract Infection Clinical Trial 2023: Phage Therapy Highlights & Side Effects. Trial Name: NCT05537519 — Phase 1 & 2

Phage Therapy (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05537519 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers currently enrolling participants for this experiment?

"Information accessible on clinicaltrials.gov states that this trial is no longer recruiting patients, with the initial post published October 15th 2022 and the last edit being September 9th of the same year. Despite not actively searching for new candidates, there are 791 other medical trials presently enrolling participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Phage Therapy for the Treatment of Urinary Tract Infection

Gregory German 2023. "Phage Therapy for the Treatment of Urinary Tract Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05537519.